CVRx, Inc.

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Consensus

—

Average target

$13.00

Implied upside

—

Analysts

—

Why Is CVRX Modestly Up Today?

CVRx inched higher by $0.01 (0.29%) as the company presented late-breaking clinical data on its flagship Barostim therapy at the HFSA Annual Scientific Meeting 2026. The modest gain reflects measured investor response to the new clinical evidence being showcased at this prestigious cardiology conference.

Bottom line: CVRx's presentation of new Barostim clinical evidence at HFSA represents solid progress in the company's clinical validation efforts, but the stock's muted response suggests investors are focused on translating research into commercial results. Investors should monitor how this new data influences physician adoption rates, reimbursement coverage, and ultimately revenue growth in upcoming quarters, as clinical evidence alone is insufficient to drive meaningful stock appreciation.